Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population | Zendy

Jonathan Buber | Zendy; David Luria | Zendy; O. Gurevitz | Zendy; D. Bar-Lev | Zendy; M. Eldar | Zendy; M. Glikson | Zendy

Open Access

Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population

Author(s) -

Jonathan Buber,

David Luria,

O. Gurevitz,

D. Bar-Lev,

M. Eldar,

M. Glikson

Publication year - 2013

Publication title -

ep europace

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.119

H-Index - 102

eISSN - 1532-2092

pISSN - 1099-5129

DOI - 10.1093/europace/eut302

Subject(s) - medicine , implantable cardioverter defibrillator , primary prevention , ventricular tachycardia , shock (circulatory) , ventricular fibrillation , population , secondary prevention , beneficiary , intensive care medicine , cardiology , finance , environmental health , disease , economics

Strategically chosen ventricular tachycardia (VT)/ventricular fibrillation (VF) detection and therapy parameters aimed at reducing shock deliveries were proven effective in studies that utilized single manufacturer devices with a follow-up of up to 1 year. Whether these beneficiary effects can be generalized to additional manufacturers and be maintained for longer periods is to be determined. Our aim was to evaluate the durability and applicability of the programming of strategic implantable cardioverter-defibrillators (ICDs) of various manufacturers, which is aimed at reducing the shock delivery burden in primary prevention ICD recipients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research